Xcout Intel
Spiderwort
Spiderwort Biotechnologies Inc. is an Ottawa-based biotechnology innovator specializing in all-natural, plant-based biomaterials designed to support tissue regeneration and repair spinal cord injuries.
Subscribe to see Spiderwort’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Spiderwort at a glance
Spiderwort is a biotech company headquartered in Canada. It has raised at least $15.7M across the 2 funding rounds on record. Its most recent funding round, Series A, raised $13.2M in July 2022. Xcout tracks 8 named people at Spiderwort, including Scott Jarvis (Chief Financial Officer).
Spiderwort leadership
- Scott JarvisChief Financial Officer
- Charles M. CuerrierChief Executive Officer | Co-founder
- Andrew E. PellingChief Scientific Officer | Co-founder
- Jessica JonasBusiness Development Director, Aesthetics
- Stephen HansonBusiness Development Director
- Dane BedwardBoard Chairman
2 more named people on record for Spiderwort, with roles, board committees and tenure — see the full roster →
Spiderwort funding rounds
At least $15.7M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series A | $13.2M | 7 named | |
| — | $2.5M | 7 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Spiderwort competitors
A few of Spiderwort's closest competitors — see the full list of competitors and alternatives →
CryoStasis is a biotechnology company headquartered in Ottawa, Canada, specializing in the subzero unfrozen bio-preservation of cells, tissues, and organs.
SpinalCyte is a U.S. biotechnology company developing regenerative, cell-based therapies for spinal disorders, particularly degenerative disc disease. Its work has focused on injectable allogeneic cell therapies intended to repair or regenerate damaged intervertebral discs, serving patients with spinal degeneration.
NurExone Biologic Inc., a pharmaceutical technology company, develops a platform for biologically guided exosome-based therapies for the treatment of central nervous system injuries. Its lead product, ExoPTEN, has demonstrated strong preclinical data supporting clinical potential in treating acute spinal cord and optic nerve injury. The company was founded on June 27, 2011 and is headquartered in Toronto, Canada.
Axonis Therapeutics, Inc. is a biotechnology company headquartered in Boston, Massachusetts, focused on discovering and developing novel treatments for neurological conditions and spinal cord injuries. Founded in 2019, the company advances therapeutic candidates through its proprietary research platform.
Amplicore Inc. develops injectable therapeutics aimed at treating degenerative musculoskeletal disorders such as osteoarthritis, cartilage damage, degenerative disc disease, and acute meniscus tears. The company focuses on regenerative and minimally invasive approaches to address the underlying causes of joint discomfort and restore mobility for patients.
NervGen Pharma Corp. is a biotechnology enterprise currently in its clinical development phase, focused on devising therapeutic solutions for nerve injuries and progressive neurodegenerative diseases. Their innovative approach centers on deactivating the natural biological mechanisms that typically impede the nervous system's ability to repair itself.
Get Spiderwort's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Spiderwort in Xcout Intel
- 8 named people with titles, LinkedIn and board committees
- 2 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access